Size and composition of synthetic calcium sulfate beads influence dissolution and elution rates in vitro
Randy Roberts
Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210
Search for more papers by this authorStephen J. McConoughey
Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210
Search for more papers by this authorCorresponding Author
Jason H. Calhoun
Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210
Correspondence to: J. H. Calhoun (e-mail: [email protected]Search for more papers by this authorRandy Roberts
Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210
Search for more papers by this authorStephen J. McConoughey
Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210
Search for more papers by this authorCorresponding Author
Jason H. Calhoun
Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210
Correspondence to: J. H. Calhoun (e-mail: [email protected]Search for more papers by this authorAll Stimulan® was provided to the researchers free of charge.
Abstract
Treatments of osteomyelitis lag behind bacterial resistance to antibiotics. We tested different-sized calcium sulfate beads and their ability to elute multiple antibiotics in vitro as a possible method to improve the therapeutic delivery in patients. Two sizes of calcium sulfate beads (4.8 and 3.0 mm diameter) that contained vancomycin, tobramycin, or both were dissolved in phosphate-buffered saline, and the rate of dissolution by weight and antibiotic elution by the disc diffusion assay and high-pressure liquid chromatography were measured. The 4.8 mm beads showed significantly higher dissolution rates relative to the 3.0 mm beads (2.3 mg/day vs. 1.3 mg/day). While the vancomycin-loaded 4.8 mm beads eluted for a longer time relative to the 3.0 mm beads (20 days vs. 10 days), the smaller beads had threefold higher elution for the first 2 days, before dropping to near zero elution by day 4. The presence of tobramycin extended the elution of the vancomycin to day 40, which closely matches the recommended 6 weeks to treat orthopedic staphylococcus infections. These data suggest that size and content of the bead are variables that could affect their clinical success, and both could be exploited to tailor treatments of specific infections and injuries. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 102B: 667–673, 2014.
REFERENCES
- 1 Ubukata K, Nonoguchi R, Matsuhashi M, Konno M. Expression and inducibility in Staphylococcus aureus of the mecA gene, which encodes a methicillin-resistant S. aureus-specific penicillin-binding protein. J Bacteriol 1989; 171(5): 2882–2885.
- 2 Cierny G III, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res 2003(414): 7–24.
- 3 Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: A review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med 1970; 282(4): 198–206.
- 4 Waldvogel FA, Papageorgiou PS. Osteomyelitis: The past decade. N Engl J Med 1980; 303(7): 360–370.
- 5 Calhoun JH, Mader JT. Antibiotic beads in the management of surgical infections. Am J Surg 1989; 157(4): 443–449.
- 6 Wilson KJ, Cierny G, Adams KR, Mader JT. Comparative evaluation of the diffusion of tobramycin and cefotaxime out of antibiotic-impregnated polymethylmethacrylate beads. J Orthop Res 1988; 6(2): 279–286.
- 7 Garvin KL, Miyano JA, Robinson D, Giger D, Novak J, Radio S. Polylactide/polyglycolide antibiotic implants in the treatment of osteomyelitis. A canine model. J Bone Joint Surg Am 1994; 76(10): 1500–1506.
- 8 Humphrey JS, Mehta S, Seaber AV, Vail TP. Pharmacokinetics of a degradable drug delivery system in bone. Clin Orthop Relat Res 1998(349): 218–224.
- 9 Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 2000; 59(6): 1223–1232.
- 10 Shinto Y, Uchida A, Korkusuz F, Araki N, Ono K. Calcium hydroxyapatite ceramic used as a delivery system for antibiotics. J Bone Joint Surg Br 1992; 74(4): 600–604.
- 11 Wichelhaus TA, Dingeldein E, Rauschmann M, Kluge S, Dieterich R, Schafer V, Brade V. Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. J Antimicrob Chemother 2001; 48(1): 117–119.
- 12 Cerretani D, Giorgi G, Fornara, Bocchi L, Neri L, Ceffa R, Ghisellini F, Ritter MA. The in vitro elution characteristics of vancomycin combined with imipenem-cilastatin in acrylic bone-cements: A pharmacokinetic study. J Arthroplasty 2002; 17(5): 619–626.
- 13 Kanellakopoulou K, Galanakis N, Giamarellos-Bourboulis EJ, Rifiotis C, Papakostas K, Andreopoulos A, Dounis E, Karagianakos P, Giamarellou H. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. J Antimicrob Chemother 2000; 46(2): 311–314.
- 14 Kanellakopoulou K, Panagopoulos P, Giannitsioti E, Tsaganos T, Carrer DP, Efstathopoulos N, Giamarellos-Bourboulis EJ. In vitro elution of daptomycin by a synthetic crystallic semihydrate form of calcium sulfate, stimulan. Antimicrob Agents Chemother 2009; 53(7): 3106–3107.
- 15 Lazarettos J, Efstathopoulos N, Papagelopoulos PJ, Savvidou OD, Kanellakopoulou K, Giamarellou H, Giamarellos-Bourboulis EJ, Nikolaou V, Kapranou A, Papalois A, Papachristou G. A bioresorbable calcium phosphate delivery system with teicoplanin for treating MRSA osteomyelitis. Clin Orthop Relat Res 2004(423): 253–258.
- 16 Panagopoulos P, Tsaganos T, Plachouras D, Carrer DP, Papadopoulos A, Giamarellou H, Kanellakopoulou K. In vitro elution of moxifloxacin and fusidic acid by a synthetic crystallic semihydrate form of calcium sulphate (Stimulan). Int J Antimicrob Agents 2008; 32(6): 485–487.
- 17 Penner MJ, Masri BA, Duncan CP. Elution characteristics of vancomycin and tobramycin combined in acrylic bone–cement. J Arthroplasty 1996; 11(8): 939–944.
- 18 Moore WR, Graves SE, Bain GI. Synthetic bone graft substitutes. ANZ J Surg 2001; 71(6): 354–361.
- 19 Peltier LF. The use of plaster of Paris to fill defects in bone. Clin Orthop 1961; 21: 1–31.
- 20 Bowyer GW, Cumberland N. Antibiotic release from impregnated pellets and beads. J Trauma 1994; 36(3): 331–335.
- 21 Chotanaphuti T, Surijamorn P, Luenam S, Ongnamthip P. In vitro antimicrobial activity of phramongkutklao hydroxyapatite antibiotic pellet. J Med Assoc Thai 2008; 91(12): 1868–1872.
- 22 Gitelis S, Brebach GT. The treatment of chronic osteomyelitis with a biodegradable antibiotic-impregnated implant. J Orthop Surg (Hong Kong) 2002; 10(1): 53–60.
- 23 Nelson CL, McLaren SG, Skinner RA, Smeltzer MS, Thomas JR, Olsen KM. The treatment of experimental osteomyelitis by surgical debridement and the implantation of calcium sulfate tobramycin pellets. J Orthop Res 2002; 20(4): 643–647.
- 24 Richelsoph KC, Webb ND, Haggard WO. Elution behavior of daptomycin-loaded calcium sulfate pellets: A preliminary study. Clin Orthop Relat Res 2007; 461: 68–73.
- 25 Trippel SB. Antibiotic-impregnated cement in total joint arthroplasty. J Bone Joint Surg Am 1986; 68(8): 1297–1302.
- 26 Gauland C. Managing lower-extremity osteomyelitis locally with surgical debridement and synthetic calcium sulfate antibiotic tablets. Adv Skin Wound Care 2011; 24(11): 515–523.
- 27 Zhang Z, Zhang C, Guo QF, Shen LF, Zhang XW. Application of vancomycin-loaded calcium sulphate in treatment of osteomyelitis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2013; 35(3): 337–342.
- 28 Kluin OS, van der Mei HC, Busscher HJ, Neut D. Biodegradable vs non-biodegradable antibiotic delivery devices in the treatment of osteomyelitis. Expert Opin Drug Deliv 2013; 10(3): 341–351.
- 29 Beuerlein MJ, McKee MD. Calcium sulfates: What is the evidence? J Orthop Trauma 2010; 24 Suppl 1: S46–S51.
- 30 Helgeson MD, Potter BK, Tucker CJ, Frisch HM, Shawen SB. Antibiotic-impregnated calcium sulfate use in combat-related open fractures. Orthopedics 2009; 32(5): 323.
- 31 Thomas DB, Brooks DE, Bice TG, DeJong ES, Lonergan KT, Wenke JC. Tobramycin-impregnated calcium sulfate prevents infection in contaminated wounds. Clin Orthop Relat Res 2005; 441: 366–371.
- 32 Ham K, Griffon D, Seddighi M, Johnson AL. Clinical application of tobramycin-impregnated calcium sulfate beads in six dogs (2002–2004). J Am Anim Hosp Assoc 2008; 44(6): 320–326.
- 33 Sandoe JA, Wysome J, West AP, Heritage J, Wilcox MH. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. J Antimicrob Chemother 2006; 57(4): 767–770.
- 34 Tambe SM, Sampath L, Modak SM. In vitro evaluation of the risk of developing bacterial resistance to antiseptics and antibiotics used in medical devices. J Antimicrob Chemother 2001; 47(5): 589–598.
- 35 Shinsako K, Okui Y, Matsuda Y, Kunimasa J, Otsuka M. Effects of bead size and polymerization in PMMA bone cement on vancomycin release. Biomed Mater Eng 2008; 18(6): 377–385.
- 36 Papagelopoulos PJ, Mavrogenis AF, Tsiodras S, Vlastou C, Giamarellou H, Soucacos PN. Calcium sulphate delivery system with tobramycin for the treatment of chronic calcaneal osteomyelitis. J Int Med Res 2006; 34(6): 704–712.
- 37
Sanicola SM,
Albert SF. The in vitro elution characteristics of vancomycin and tobramycin from calcium sulfate beads. J Foot Ankle Surg 2005; 44(2): 121–124.
10.1053/j.jfas.2005.01.006 Google Scholar
- 38 Wahl P, Livio F, Jacobi M, Gautier E, Buclin T. Systemic exposure to tobramycin after local antibiotic treatment with calcium sulphate as carrier material. Arch Orthop Trauma Surg 2011; 131(5): 657–662.